+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Rituxan"

Lymphoma Therapeutics - Global Strategic Business Report - Product Thumbnail Image

Lymphoma Therapeutics - Global Strategic Business Report

  • Report
  • February 2025
  • 406 Pages
  • Global
From
Cancer Monoclonal Antibodies Market Report 2025 - Product Thumbnail Image

Cancer Monoclonal Antibodies Market Report 2025

  • Report
  • March 2025
  • 250 Pages
  • Global
From
Diffuse Large B-Cell Lymphoma Therapeutics Market Report 2025 - Product Thumbnail Image

Diffuse Large B-Cell Lymphoma Therapeutics Market Report 2025

  • Report
  • February 2025
  • 200 Pages
  • Global
From
From
From
From
From
From
Central Nervous System Lymphoma - Pipeline Insight, 2024 - Product Thumbnail Image

Central Nervous System Lymphoma - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 40 Pages
  • Global
From
From
From
From
Loading Indicator

Rituxan (rituximab) is a monoclonal antibody used to treat a variety of immune disorders, including non-Hodgkin's lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, and granulomatosis with polyangiitis. It is used in combination with other drugs to treat these conditions. Rituxan works by targeting and destroying B-cells, which are a type of white blood cell involved in the body's immune response. Rituxan is a biologic drug, meaning it is made from living cells. It is administered intravenously and is typically given in two doses, two weeks apart. The drug has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of certain immune disorders. Rituxan is a widely used drug in the immune disorders market. It is one of the most prescribed drugs for the treatment of non-Hodgkin's lymphoma and rheumatoid arthritis. It is also used off-label to treat other conditions, such as systemic lupus erythematosus. Some companies in the Rituxan market include Genentech, Biogen, and Roche. Show Less Read more